Alcheimera slimeibys prognoze parostai ir švaka, deļtam ka tei ir progresejūša i degeneraceja, kurai nav zynoma zuole.
Progresa uotrums dažaidim cylvākim ir atškireigs, tok slimeiba laika gaitā parosti palīk švakuoka, nūvadūt pi kognitivūs i fiziskūs spieju sasamazynuošonys.
Asūt progresejūšai slimeibai, individi var zaudēt atmiņu, apgryutynuot volūdu i komunikaceju, dezorientejuotīs i maineitīs humora i uzvedeibys izjiutu.
Vysbeidzūt jī var palikt naaizsorguoti i jim ir vajadzeiga paleidzeiba.
Vydyskais dzeivis garums piec diagnozis ir ap 8 - 10 godim, tok tys var cīši atsaškiert atkareibā nu individuala vacuma, vyspuorejuos veseleibys i cytu faktoru.
Koč i nav zuoļu pret Alcheimera slimeibu, tuos simptomys var tikt kontrolātys i var uzlobuot dzeivis kvalitati.
Kaldjian LC: Survival versus prognosis in Alzheimer disease. Ann Intern Med. 2004, 141 (7): 575; author reply 575.
Mayeux R, Stern Y, Sano M: Heterogeneity and prognosis in dementia of the Alzheimer type. Bull Clin Neurosci. 1985, 50 (): 7-10.
DeKosky ST, Golde T: Cerebrospinal Biomarkers in Alzheimer Disease-Potential Roles as Markers of Prognosis and Neuroplasticity. JAMA Neurol. 2016, 73 (5): 508-10.
Yaffe K: Treatment of Alzheimer disease and prognosis of dementia: time to translate research to results. JAMA. 2010, 304 (17): 1952-3.
Zhu B, Chen X, Li W, Zhou D: Effect of Alzheimer Disease on Prognosis of Intensive Care Unit (ICU) Patients: A Propensity Score Matching Analysis. Med Sci Monit. 2022, 28 (): e935397.
Malpetti M, Joie R, Rabinovici GD: Tau Beats Amyloid in Predicting Brain Atrophy in Alzheimer Disease: Implications for Prognosis and Clinical Trials. J Nucl Med. 2022, 63 (6): 830-832.
Schaeffer EL, Figueiro M, Gattaz WF: Insights into Alzheimer disease pathogenesis from studies in transgenic animal models. Clinics (Sao Paulo). 2011, 66 Suppl 1 (): 45-54.
Bhagwat N, Pipitone J, Voineskos AN, Chakravarty MM: An artificial neural network model for clinical score prediction in Alzheimer disease using structural neuroimaging measures J Psychiatry Neurosci. 2019, 44 (4): 246-260.
Vermunt L, van Paasen AJL, Teunissen CE, Scheltens P, Visser PJ, Tijms BM: Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal. Neurology. 2019, 92 (23): e2699-e2705.
Raji MA, Brady SR: Mirtazapine for treatment of depression and comorbidities in Alzheimer disease. Ann Pharmacother. 2001, 35 (9): 1024-7.
['Atsaceišona nu: medicinys']
['Itei interneta vītne ir dūmuota tikai izgleiteibys i informacejis īmeslim, i tei nateik skaiteita par medicinys pīduovuojumu voi profesionalu pakolpuojumu.']
['Pīduovuotū informaceju nadreikst lītuot, kab diagnosticātu voi izuorstātu kaidu slimeibu, i tim, kas meklej personeigu mediciniskū padūmu, juosazynoj ar licencātu uorstu.']
['Juopīzeist, ka neironu teikls, kas generej atbiļdis iz vaicuojumim, ir eipaši napareizs, kod runoj par skaitliskū saturu, par pīmāru, par konkretu slimeibu diagnozātūs cylvāku skaitu.']
['Vysod meklejit padumu nu sova uorsta voi cyta kvalificāta uorsta, kab saprostu jiusu slimeibu. Nikod naatsakuortojit profesionalū uorsta padumu voi aizkavejit tū mekliešonu deļtuo, ka esat koč kū izlasiejs itamā interneta vītnē. Ka jiusim ruodīs, ka jiusim var byut uorsteibys uorkuortys situaceja, zvaniet 911 voi īīt tyvuokajā uorstnīceibys centrā.']
['Atsaceišona: autortiesības']
['1998. goda Digitaluo tyukstūšgadis autoru tīseibu lykums, 17 U.S.C. § 512 (DMCA) nūdrūsynoj tīseibu aizstuoviešonu autoru tīseibu turātuojim, kuri skaita, ka materialā, kas pasaruoda iz škārsteikla, ir puorkuoptys jūs tīseibys saskaņā ar ASV autoru tīseibu lykumim. ']
['Ka jius iz lobu tycat, ka kaids saturs voi materials, kas ir pīejams saisteibā ar myusu sātom voi pakolpuojumim, puorkuop jiusu autortiesības, jius (voi jiusu aģents) jiusim var syuteit paziņuojumu, kurā lyugts svīgt itū saturu voi materialu voi bloķēt pīeju tam.']
['Paziņuojumi ir juonūsyuta e-postā (vērtīs sadaļu "Kontakti" e-posta adresei).']
['DMCA prasej, kab jiusu paziņuojumā par īspiejamu autortiesību puorkuopumu byutu īkļauta itei informaceja: (1) ar autortiesībām aizsorguotuo dorba aproksts, kas ir īspiejamuos puorkuopuma objekts; (2) īspiejamuos puorkuopuma satura aproksts i informaceja, kas ir pīteikama, kab ļautu mums atrast saturu; (3) jiusu kontaktinformaceja, tymā skaitā adrese, telefona numurs i e-posta adrese; (4) apstyprynuojums, ka jius asat puorlīcynuots, ka saturs tai, kai ir ībyldts, nav atļauts ar autortiesību eipašnīka voi juo aģenta voi kaida lykuma atbolstu; ']
['5. aplīcynuojumu, ka jiusu informaceja ir pareiza i ka jiusim ir tīseibys izmontuot autortīseibys, kuruos ir nūlīgts lītuot;']
['i 6) fizisks voi elektronisks autortīseibu turātuoja voi personas, kas ir pilnvarota dorbuotīs autortīseibu turātuoja vuordā, paraksts.']
['Lyudzu, syutiet mums e-postu ar sevkuru vaicuojumu/ieteikumu.']
What is prognosis of alzheimer?
The prognosis of Alzheimer's disease is generally poor, as it is a progressive and degenerative condition with no known cure.
The rate of progression varies from person to person, but the disease typically worsens over time, leading to a decline in cognitive and physical abilities.
As the disease progresses, individuals may experience memory loss, difficulty with language and communication, disorientation, and changes in mood and behavior.
Eventually, they may become unable to care for themselves and require full-time assistance.
The average life expectancy after diagnosis is around 8-10 years, but this can vary widely depending on the individual's age, overall health, and other factors.
While there is no cure, treatments and therapies can help manage symptoms and improve quality of life for those with Alzheimer's disease.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
